Abstract 421P
Background
Tumors deficient in DNA repair mechanism, particularly the HRR including BRCA (somatic and /or germline ) are sensitive to Platinum chemotherapy, PARP inhibitors (PARPi), and immunotherapy (IO) in cancers like breast and ovarian, however, clinical trials are ongoing in pancreatic, prostate, endometrial and other cancer types which have progressed on first-line chemotherapy. In this study, CGP identified the landscape of sBRCA and HRR as potential biomarkers across the multi-cancer cohort.
Methods
950 biopsy proven patient samples at HCG were profiled using Illumina TruSight Oncology 500 assay on NextSeq2000 in an IRB-approved study. Sequenced data was processed by StrandOmics platform.
Results
About 142 (15 %) patients in the studied cohort of multiple cancer types were found with alterations in sBRCA and HRR pathway. 208 mutations were detected across 950 cases with 66 cases reporting ≥ 1 HRR gene alterations (mean incidence of 1.4/case). 37 HRR cases were associated with elevated tumor mutation burden. sBRCA1 and sBRCA2 were found in 22 and 27 patients respectively accounting for 3% HRR pathway. Other HRR genes included ATM, RAD51, PTEN, ATRX, PALB2, MRE11A, RAD50, CDK12, ARID1A and PTEN in 12 % of HRR pathway. It is noteworthy that sBRCA and HRR gene alterations were found across diverse cancers, highest in gastrointestinal followed by breast cancer (TNBC-56%) (Table). Apart from FDA approved cancers (n=57), HRR alteration were prevalent across other diverse cancers (n=85) in the cohort. 60% patients with sBRCA and HRR mutations treated with platinum / PARPi as NACT, achieved partial to pathological complete response (pCR) while 5 cases treated with IO are on follow up. Table: 421P
Prevalence of sBRCA and HRR genes across the multi-cancer cohort of 950 cases
Cancer | N=142 HRR+ve cases (%) | Major HRR alterations |
Gastrointestinal | 33 (23%) | ATM, ARID1A, BRCA1, PTEN, MRE11 |
Breast | 23 (16%) | BRCA1, PTEN, PALB2, ARID1A, ATM |
Triple-negative breast cancer (TNBC) | 13 (56% of Breast cancer cases with HRR alterations) | BRCA1, BRCA2, PTEN, BAP1, PALB2 |
Female genital tract | 20 (14%) | BRCA1, ARID1A, PTEN, RAD54L |
Lung | 19 (13%) | PTEN, ATM, BRCA1, ARID1A |
Head & neck | 13 (9%) | PTEN, ARID1A, ATM, BARD1, RAD50 |
Sarcoma | 10 (7%) | ATRX, PTEN, BRCA2, PALB2 |
Genitourinary | 10 (7%) | CDK12, BRCA1, PTEN |
Other cancers | 9 (6%) | PTEN, ARID1A, BAP1, RAD50 |
Carcinoma of unknown origin | 5 (4%) | ARID1A, ATRX, PTEN |
Conclusions
CGP identified sBRCA and HRR mutations in wide spectrum of cancers enabling the utility of PARPi as maintenance therapy, hence necessitating sBRCA and HRR testing as standard of care besides germline testing for personalized therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B.S. Ajaikumar: Financial Interests, Institutional, Member of Board of Directors, Executive Chairman: HCG. All other authors have declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract